Is Vancouver Canada's supervised injection facility cost-saving?

Addiction

Volumn 105, Issue 8, 2010, Pages 1429-1436

  Pinkerton, Steven D ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Cost effectiveness; HIV transmission; injection drug use; mathematical model; supervised injection facility; syringe exchange

Indexed keywords

ARTICLE; CANADA; COST BENEFIT ANALYSIS; COST CONTROL; DRUG ABUSE; ECONOMICS; HEALTH CARE COST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; ORGANIZATION AND MANAGEMENT; PREVALENCE; PREVENTIVE HEALTH SERVICE; STATISTICAL MODEL; STATISTICS; SUBSTANCE ABUSE; SYRINGE; URBAN POPULATION;

BRITISH COLUMBIA; COST SAVINGS; COST-BENEFIT ANALYSIS; HEALTH CARE COSTS; HIV INFECTIONS; HUMANS; INCIDENCE; MODELS, STATISTICAL; NEEDLE SHARING; NEEDLE-EXCHANGE PROGRAMS; PREVALENCE; SUBSTANCE ABUSE, INTRAVENOUS; SYRINGES; URBAN POPULATION;

EID: 77954469769     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/j.1360-0443.2010.02977.x     Document Type: Article

References (44)

1. British Columbia Centre for Disease Control. HIV/AIDS Annual Report.
2. Public Health Agency of Canada. HIV and AIDS in Canada. Surveillance Report to December 31, 2007.
3. Health Canada. Vancouver's INSITE Service and Other Supervised Injection Sites. What Has Been Learned from Research? Final Report of the Expert Advisory Committee on Supervised Injection Site Research.
4. Milloy M.-J., Wood E. Emerging role of supervised injecting facilities in human immunodeficiency virus prevention. Addiction 2009 104 : 620 621.
5. Wood E., Tyndall M. W., Montaner J. S., Kerr T. Summary of findings from the evaluation of a pilot medically supervised safer injecting facility. Can Med Assoc J 2006 175 : 1399 1404.
6. Kerr T., Tyndall M. W., Lai C., Montaner J. S. G., Wood E. Drug-related overdoses within a medically supervised safer injection facility. Int J Drug Policy 2006 17 : 436 441.
7. Milloy M.-J. S., Kerr T., Tyndall M., Montaner J., Wood E. Estimated drug overdose deaths averted by North America's first medically-supervised safer injection facility. PLoS ONE 2008 3 : e3351. doi:10.1371/journal.pone.0003351.
8. Wood E., Tyndall M. W., Zhang R., Montaner J. S. G., Kerr T. Rate of detoxification service use and its impact among a cohort of supervised injecting facility users. Addiction 2007 102 : 916 919.
9. Buxton J. Vancouver Drug Use Epidemiology: Site Report for the Canadian Community Epidemiology Network on Drug Use. Vancouver, BC: Canadian Community Epidemiology Network on Drug Use, 2007. Available from http://vancouver.ca/ fourpillars/documents/Full-CCENDU-report-2007-web.pdf (accessed 15 May 2010). Archived at http://www.webcitation.org/5qWyjGzKQ (16 June 2010).
10. Tyndall M. W., Kerr T., Zhang R., King E., Montaner J. G., Wood E. Attendance, drug use patterns, and referrals made from North America's first supervised injection facility. Drug Alcohol Depend 2005 83 : 193 198.
11. Kerr T., Tyndall M. W., Li K., Montaner J. S., Wood E. Safer injecting facility use and syringe sharing among injection drug users. Lancet 2005 366 : 316 318.
12. Wood E., Kerr T., Small W., Li K., Marsh D. C., Montaner J. S. G. et al. Changes in public order after the opening of a medically supervised safer injection facility for drug users. Can Med Assoc J 2004 171 : 731 734.
13. Stoltz J., Wood E., Small W., Li K., Tyndall M., Montaner J. et al. Changes in injecting practices associated with the use of a medically supervised safer injection facility. J Public Health 2007 29 : 35 9.
14. Wood E., Tyndall M. W., Lai C., Montaner J. S. G., Kerr T. Impact of a medically supervised safer injecting facility on drug dealing and other drug-related crime. Subst Abuse Treat Prev Policy 2006 1 : 13.
15. Kerr T., Stoltz J., Tyndall M., Li K., Zhang R., Montaner J. Impact of a medically supervised safer injection facility on community drug use patterns: a before and after study. BMJ 2006 332 : 220 222.
16. Drucker E. Insite: Canada's landmark safe injecting program at risk. Harm Reduct J 2006 3 : 24.
17. Mulgrew I. BC court makes a courageous decision to support Insite. Vancouver Sun May 28, 2008.
18. Webster P. Court halts closure of Canada's safe-injection site. Lancet 2008 371 : 1985.
19. Andresen M., Boyd N. A cost-benefit and cost-effectiveness analysis of Vancouver's safe injection facility. Unpublished manuscript. 2008. Available at: http://www2.canada.com/vancouversun/pdf/finalcost-benefitanalysis-.pdf (accessed 15 May 2010). Archived at http://www.webcitation.org/5qWz2tv9c (16 June 2010).
20. Bayoumi A. M., Zaric G. S. The cost-effectiveness of Vancouver's supervised injection facility. CMAJ 2008 179 : 1143 1151.
21. Des Jarlais D. C., Kamyar Arasteh K., Hagan H. Evaluating Vancouver's supervised injection facility: data and dollars, symbols and ethics. Can Med Assoc J 2008 179 : 1105 1106.
22. McInnes C. W., Druyts E., Harvard S. S., Gilbert M., Tyndall M. W., Lima V. D. et al. HIV/AIDS in Vancouver, British Columbia: a growing epidemic. Harm Reduct J 2009 6 : 5.
23. Tyndall M. W., Wood E., Zhang R., Lai C., Montaner J. S. G., Kerr T. HIV seroprevalence among participants at a Supervised Injection Facility in Vancouver, Canada: implications for prevention, care and treatment. Harm Reduct J 2006 3 : 36.
24. Tengs T. O., Adams M. E., Pliskin J. S., Safran D. G., Siegel J. E., Weinstein M. C. et al. Five-hundred life-saving interventions and their cost-effectiveness. Risk Anal 1995 15 : 369 390.
25. Kaplan E. H., O'Keefe E. Let the needles do the talking: evaluation the New Haven needle exchange. Interfaces 1993 23 : 7 26.
26. Kaplan E. H. Economic analysis of needle exchange. AIDS 1995 9 : 1113 1119.
27. Albert T., Williams G., Legowski B., Remis R. The Economic Burden of HIV/AIDS in Canada (CPRN Study no. H-02).
28. Kahn J. G. Are NEPs cost-effective in preventing HIV infection? In : Lurie P., Reingold A. L., editors. Public Health Impact of Needle Exchange Programs in the United States and Abroad.
29. Tyndall M., Kerr T., Lai C., Shannon K., Wood E., Montaner J. Persistently high rates of HIV transmission among illicit drug users in Vancouver, Canada, 1995-2004. XVI International AIDS Conference: March 13-18, 2006. Abstract: MOPE0426.
30. Remis R. S., Bruneau J., Hankins C. A. Enough sterile syringes to prevent HIV transmission among injection drug users in Montreal? J AIDS 1998 18 : S57 S59.
31. Health Canada. I-Track - Enhanced Surveillance of Risk Behaviours among Injecting Drug Users in Canada. Pilot Survey Report.
32. McCoy C. B., Metsch L. R., Chitwood D. D., Shapshak P., Comerford S. T. Parenteral transmission of HIV among injection drug users: assessing the frequency of multiperson use of needles, syringes, cookers, cotton, and water. J AIDS 1998 18 : S25 S29.
33. Singer M., Himmelgreen D., Dushay R., Weeks M. R. Variation in drug injection frequency among out-of-treatment drug users in a national sample. Am J Drug Alcohol Abuse 1998 24 : 321 341.
34. Wood E., Tyndall M. W., Spittal P. M., Li K., Kerr T., Hogg R. S., et al. Unsafe injection practices in a cohort of injection drug users in Vancouver: could safer injecting rooms help? CMAJ 2001 165 : 405 410.
35. Wood E., Tyndall M., Stoltz J., Small W., Lloyd-Smith E., Zhang R. et al. Factors associated with syringe sharing among users of a medically supervised safer injecting facility. Am J Infect Dis 2005 1 : 50 4.
36. Day B. Ottawa's bad prescription on addiction. The Star June 8, 2008. Available at: http://www.thestar.com/comment/article/438967 (accessed 15 May 2010).
37. Hathaway A., Tousaw K. Harm reduction headway and continuing resistance: insights from safe injection in the city of Vancouver. Int J Drug Policy 2008 19 : 11 6.
38. Hwang S. W. Science and ideology. Open Med 2007 1. Available at: http://www.openmedicine.ca/article/viewArticle/128/52 (accessed 15 May 2010).
39. Webster P. Fixed: how the Harper government wasted millions and alienated academe in its campaign to shut Insite. Vancouver Magazine 1 January, 2009.
40. Allard R. A mathematical model to describe the risk of infection from sharing injection equipment. J AIDS 1990 3 : 1010 1016.
41. Cheng F. Y., Ford W. L., Weber M. D., Cheng S.-Y., Kerndt P. R. A probability-based approach for rpedicting HIV infection in a low prevalent population of injection drug users. Ann Epidemiol 1997 7 : 28 34.
42. Holtgrave D. R., Pinkerton S. D., Jones T. S., Lurie P., Vlahov D. Cost and cost-effectiveness of increasing access to sterile syringes and needles as an HIV prevention intervention in the United States. J AIDS 1998 18 : S133 S138.
43. Kaplan E. H. Modeling HIV infectivity: must sex acts be counted? J AIDS 1990 3 : 55 61.
44. Pinkerton S. D., Abramson P. R. The Bernoulli-process model of HIV transmission: applications and implications. In : Holtgrave D. R., editor. Handbook of Economic Evaluation of HIV Prevention Programs.